Copyright
©The Author(s) 2021.
World J Gastroenterol. May 28, 2021; 27(20): 2474-2494
Published online May 28, 2021. doi: 10.3748/wjg.v27.i20.2474
Published online May 28, 2021. doi: 10.3748/wjg.v27.i20.2474
Table 4 Summary of results of clinical trials of hepatitis B antiviral therapy in children
| Interferon-α-2b | Lamivudine | Adefovir | Tenofovir DF | Entecavir | Pegylated interferon-α-2a | |
| Number treated | 144 | 191 | 173 | 52 | 120 | 101 |
| Duration of treatment in wk | 24 | 52 | 48 | 72 | 48 | 48 |
| Age, median (range) | 5 (1-17) | 9 (2-17) | 11 | 15.5 (12-17) | 12 (2-17) | 11 (3-7) |
| Virological response as HBeAg negative HBV DNA undetectable (% treated vs placebo) | 26 (vs 11) | 23 (vs 13) | 10.6 (vs 0) | 21.2 (vs 0) | 24.2 (vs 3.3) | 19.8 (vs 2) |
| HBsAg negative (% treated vs placebo) | 10 (vs 1) | 2 (vs 0) | 0.8 (vs 0) | 1.9 (vs 0) | 5.8 (vs 0) | 8.9 (0) |
| Ref. | Sokal et al[97] | Jonas et al[98] | Jonas et al[99] | Murray et al[100] | Jonas et al[101] | Wirth et al[102] |
- Citation: Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494
- URL: https://www.wjgnet.com/1007-9327/full/v27/i20/2474.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i20.2474